ZYDUSLIFE

ZydusLife receives final approval from #USFDA for Eluxadoline Tablets

Zydus Lifesciences has received USFDA approval to manufacture Eluxadoline Tablets (75 mg and 100 mg) for treating irritable bowel syndrome with diarrhea. The company is eligible for 180 days of shared generic exclusivity, with 419 approvals and 483 filed ANDAs.